8-K current report · filed Sep 29, 2026

Cartesian Therapeutics, Inc. (RNAC) 8-K Current Report: September 29, 2026

Item 8.01Item 7.01RNAC overview

Short answer

Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Phase 2 Descartes-08 retreatment data update in myasthenia gravis.

Cartesian Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Phase 2 Descartes-08 retreatment data update in myasthenia gravis
  • Additional clinical data may influence confidence in durability and retreatment strategy
  • Full efficacy and safety details in Exhibit 99.1 press release

Item 8.01 · Other Events

  • Five MG patients retreated after symptom recurrence at median 16.6 months following initial Descartes-08 treatment
  • Month 12 post-retreatment outcomes: MG-ADL reduction 6.6 points and MGC reduction 15 points from baseline
  • All patients achieved clinically meaningful MGC and MG-ADL improvements; four sustained MG-ADL benefit through Month 12
  • Retreatment showed no serious adverse events and no cytokine release syndrome, neurotoxicity, cytopenias, or hypogammaglobulinemia
  • Findings support potential repeat dosing, strengthening Descartes-08’s durability and retreatment profile in MGેણ

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cartesian Therapeutics, Inc. 8-K filings

Get the next RNAC 8-K as it lands

Follow RNAC for push alerts, or ask the research agent what this filing means.